Mushroom use dates back to ancient times, and it currently remains significant among indigenous and urban populations as a medicinal option. Psilocybe species are suggested to modify emotions when administered in macro- or microdose form for the treatment of anxiety and depression, both often affected by a delayed onset and adverse effects of current pharmacological therapy. The objective of this study was to evaluate the anxiolytic and/or antidepressant-like effects of P. cubensis mushroom aqueous extract (PcAE) microdosing in mice using open-field and rota-rod tests, followed by plus-maze or forced swimming tests. We also evaluated changes in neuronal activity and dendritic maturation using electrocorticography (ECoG) and immunohistochemical techniques. The outcomes were compared with an effective macrodose of PcAE and antidepressant fluoxetine (FLX). For this study, mice were grouped as follows: (1) vehicle, (2) acute, and (3) repeated (10 days) PcAE microdosing (1 µg/kg); (4) single PcAE macrodose (1 g/kg); and (5) acute and (6) repeated reference drug fluoxetine (FLX, 10 mg/kg).The anxiolytic and antidepressant-like effects using microdosing were similar to those observed with macrodoses of PcAE and FLX; significant dose- and/or time-dependent changes in the ECoG and dendritic maturation of hippocampus neurons were also observed, in addition to altered corticosterone levels. To conclude, P. cubensis mushroom promotes brain effects in mice after micro- and macrodosing, supporting its potential as a therapeutic alternative for mental health.
The genus Psilocybe has been characterized by central nervous system (CNS) effects and as a source of therapeutic drugs such as the alkaloids psilocybin and psilocin—secondary metabolites that produce rapid anxiolytic and antidepressant effects in preclinical and clinical studies. Furthermore, these mushrooms also contain bioactive primary metabolites, for example, the interesting case of α,α-trehalose. To explore the effects of this disaccharide, it was isolated and characterized using phytochemical and spectroscopic analyses. Subsequently, its anxiolytic- and antidepressant-like properties were assessed and corroborated by in vivo behavioral studies using experimental models for anxiety (open-field, hole-board, and plus-maze tests) and depression (forced swimming test complemented by a preliminary rota-rod test). Electrocorticographic in situ recordings and nuclear magnetic resonance analysis were also explored. Finally, an in silico docking analysis was performed to determine the involvement of the 5-HT1A serotonin receptor as one of the main targets identified in the CNS activity of Psilocybe species. The evidence shows that α,α-trehalose is one bioactive metabolite that promotes significant anxiolytic- and antidepressant-like activities mediated by early brain changes and involving an indirect participation of 5-HT1A receptors. In conclusion, α,α-trehalose represents a potential natural drug for mental health, such as in the treatment of anxiety, depression, or their comorbidity.